• 대한임상약리학회:학술대회논문집
• /
• 1994.05a
• /
• pp.65-65
• /
• 1994

• Korean Journal of Social Welfare
• /
• v.34
• /
• pp.95-119
• /
• 1998

• 대한임상약리학회:학술대회논문집
• /
• 2004.06a
• /
• pp.32-32
• /
• 2004

• Sleep Medicine and Psychophysiology
• /
• v.28 no.1
• /
• pp.1-1
• /
• 2021

• Korean Journal of Psychosomatic Medicine
• /
• v.16 no.1
• /
• pp.52-58
• /
• 2008

Objectives : Antidepressants are prescribed by not only psychiatrists but also general practitioners. However, patients' negative attitude and stigma against antidepressants are major obstacles to prescribe antidepressants in nonpsychiatric outpatient departments. We, therefore, examined patients' attitude toward antidepressant in medical and surgical group outpatient in Korea. Methods : Short item questionnaire was applied to medical group and surgical group outpatients who consented to this survey in a Korean university hospital. 100 medical and 100 surgical outpatients were surveyed. The questionnaire contained sociodemographic information, previous recognition of antidepressant, and general attitude toward attidepressants. Results : Of the 212 recipients, exclusive of erroneous and missing ones, we analyzed 200 recipients. 1) We found negative attitude toward antidepressants among both medical and surgical outpatients. 2) Medical group outpatients are answered more' antidepressants cause physically ill. 3) The persons who didn't take previously antidepressants showed more negative attitudes. 4) The most reason why they refuse to take antidepressants is concerns of side effects of antidepressants. Conclusion : There are highly negative attitude toward antidepressants between medical and surgical group outpatients. Study findings suggest the need for an active education on antidepressants to nonpsychiatric outpatients to maximize their therapeutic effect and compliance.

• Korean Journal of Biological Psychiatry
• /
• v.11 no.2
• /
• pp.127-135
• /
• 2004

Object:The goal of this study was to examine the changes in body weight and glucose levels of the patients treated with risperidone, clozapine or haloperidol in order to compare the effect of risperidone or clozapine with that of haloperidol. Methods:For nine months(January to September, 2003), a prospective study was performed in 60 patients with chronic schizophrenia who were in Seoul National Hospital. Two-week period was required for a drug wash-out. The patients were randomly assigned to risperidone, clozapine and haloperidol groups. They were given risperidone(n=20), clozapine(n=20) and haloperidol(n=20), respectively, everyday for 12 weeks. To examine the effects of these drugs on body weight and fasting glucose levels, we measured body weight and glucose levels of all the patients first without the drug treatment and at each end of 4, 8, and 12-week periods with the treatment. And we examined the differences among three groups in the changes of body weight and fasting glucose levels. Results:There were no significant differences in the changes of the body weight and fasting glucose levels between the atypical antipsychotics(risperidone or clozapine) and the typical antipsychotics(haloperidol). Conclusion:The study in the patients with chronic schizophrenia suggests that risperidone or clozapine do not cause any additional effects on body weight or glucose levels compared to haloperidol.

• Korean Journal of Psychosomatic Medicine
• /
• v.27 no.2
• /
• pp.111-118
• /
• 2019

Objectives : The purpose of this study was to investigate the clinical characteristics of antipsychotic medication prescription for the symptom control in patients with delirium. Methods : One hundred and eighty-five patients referred to consultation-liaison psychiatric services for delirium due to general medical condition were included in this study. All subjects were divided into two groups (antipsychotics users vs. antipsychotics nonusers), and comparison analyses on their clinical characteristics were performed. Results : One hundred and twenty nine patients (66.5%) used antipsychotics for their delirium, and 56 patients (30.3%) did not use antipsychotics. The history of psychotropic medication was more frequently observed in antipsychotic users (5.4% vs. 18.6%, χ²=5.498, p=0.022). Especially, the history of benzodiazepine use was significantly high in antipsychotics users. The total score and sub-items of delirium rating scale-severity items except for the psychomotor retardation item showed higher scores in antipsychotic users than in nonusers (all p<0.05). The total score of the delirium rating scale-diagnosis items was higher in antipsychotic users than in the nonusers (p=0.010). Conclusions : Delirium patients with more severe delirium symptoms and with more history of benzodiazepine use were treated with antipsychotics more frequently than those without. These findings imply that benzodiazepine may not only exacerbate delirium but be associated with aggression or psychomotor agitation that need immediate intervention. Clinicians may need to pay attention not only these external symptoms but also to hypoactive symptoms that may lead to misdiagnosis and undertreatment.

• Korean Journal of Biological Psychiatry
• /
• v.5 no.2
• /
• pp.166-174
• /
• 1998

While the therapeutic efficacy of antipsychotic drugs is not in doubt, a variety of undesirable side effects are common. They can be a disincentive to good compliance with treatment, resulting in increased possibilities for relapse and hospitalization. They can be distressing and disabling and thus interfering with patient safety and quality of life. Furthermore, they may be counter-therapeutic by exacerbating the condition that the drug was prescribed for. In this article, we will provide an overview of management of antipsychotic- induced side effects, with a particular emphasis on the most common side effects as well as less common but serious side effects. In addition, some practical issues regarding the management of side effects will be discussed.

• Korean Journal of Psychosomatic Medicine
• /
• v.16 no.2
• /
• pp.75-80
• /
• 2008

Delirium independently contributes to poor outcomes including prolonged hospital stays and increased risk of mortality. The reported prevalence of delirium in variety of medical and surgical hospital settings is from 15% to 70% ; delirium is, therefore, one of major reason for consultation that is required for psychosomatic interventions. This article reviews the psychosomatic interventions to treat delirium including 1) identification of risk factors and precipitating causes ; 2) non-pharmacological interventions, such as modifying treatment environment and educating patient's family and care-giver ; and 3) pharmacological approaches to control the various symptoms that are frequently presenting with delirium.

• Korean Journal of Biological Psychiatry
• /
• v.14 no.4
• /
• pp.232-240
• /
• 2007

Objectives : Vascular endothelial growth factor(VEGF), one of potent cytokines, and its receptors were related with various biological functions and pathological conditions. The purpose of this study was to investigate the changes of serum level of free VEGF, soluble VEGFR-1, and soluble VEGFR-2 after treatment with atypical antipsychotic drug in schizophrenia. Method : The schizophrenic patients were diagnosed with DSM-IV and were prospectively followed up for 4 and 8 weeks. Thirteen schizophrenic patients were evaluated their clinical assessment with serum levels of free VEGF, sVEGFR-1, sVEGFR-2, and positive and negative symptom scale(PANSS) at baseline, 4 weeks, and 8 weeks after treatment with atypical antipsychotic drug. Thirteen normal control subjects were recruited and matched with the patient group by age and sex. Result : The serum level of free VEGF($295.2{\pm}43.7$pg/ml)and sVEGFR-2($8259{\pm}336.7$) at baseline(before treatment) in schizophrenic patients were not significantly different, compared with the control group($199.0{\pm}28.8$ and $8481{\pm}371.9$) respectively. However, the serum level of sVEGFR-1($86.2{\pm}10.3$, p<0.05) was significantly increased in the schizophrenic patients compared with the control group($59.0{\pm}6.4$). After treatment with antipsychotic drug, the serum levels of free VEGF at 4 weeks($338.9{\pm}56.5$) and 8 weeks($309.5{\pm}58.7$) were not significantly, different compared with baseline. But the serum levels of sVEGFR-1 was significantly decreased at 8 weeks ($57.3{\pm}6.3$, p<0.05) after antipsychotic drug treatment. The serum levels of sVEGFR-2 were decreased at 4 weeks ($7761{\pm}403.0$, p<0.05) and 8 weeks($7435{\pm}333.5$, p<0.05) compared with baseline. Conclusion : The decreased serum level of sVEGFR-1 and sVEGFR-2 might be affected by dopaminergic system which was influenced by antipsychotic drug.